{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-004236","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.792873+00:00","generated_at":"2026-05-16T02:26:49.366099+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Moleculin gets Japanese patent allowance for Annamycin reconstitution methods","bullets":["Japan Patent Office issued notice of allowance for Patent App. 2021-577862 covering liposomal Annamycin preparation methods.","Patent expected to issue in coming months; complements existing US and European Annamycin patents.","Annamycin (naxtarubicin) is in Phase 3 for relapsed/refractory AML with FDA Fast Track and Orphan Drug designations.","CEO Klemp states the allowance strengthens international IP for non-cardiotoxic anthracycline therapy.","Additional Annamycin-related patent applications are pending in major jurisdictions worldwide."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-004236","json":"https://secwatch.observer/filing/0001437749-26-004236.json","markdown":"https://secwatch.observer/filing/0001437749-26-004236.md","text":"https://secwatch.observer/filing/0001437749-26-004236.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926004236/0001437749-26-004236-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926004236/mbrx20260216_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:26:49.366099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}